AccScience Publishing / BH / Volume 1 / Issue 2 / DOI: 10.36922/bh.0913
Cite this article
Journal Browser
Volume | Year
News and Announcements
View All

Autonomic nerve and its modulation approaches for heart failure

Hanyu Zhang1,2† Yanfang Zhu1,2† Siyu Chen1,2† Keqiong Deng1,2 Meng Zheng1,2 Ziyue Zeng1,2 Qiongxin Wang1,2 Huanhuan Cai1,2* Zhibing Lu1,2*
Show Less
1 Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China
2 Institute of Myocardial Injury and Repair, Wuhan University, Wuhan, China
Brain & Heart 2023, 1(2), 0913
Submitted: 6 May 2023 | Accepted: 28 June 2023 | Published: 19 July 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

Heart failure, a condition that arises from numerous cardiovascular disorders, is a primary contributor to mortality related to cardiovascular disease. Typically noticed in heart failure is heightened sympathetic activity coupled with diminished parasympathetic activity. The autonomic nervous system governs the heart’s neurological regulation through opposing functions of its sympathetic and parasympathetic components, which regulate conduction velocity, heart rate, coronary blood flow, and contractile force. Promising treatments for heart failure include inhibiting the sympathetic nerve’s overactivity and restoring parasympathetic activity in the heart. In this review, we describe neural modulation approaches that have potential to assist in the management of heart failure.

Sympathetic nerve
Parasympathetic nerve
Heart failure
National Natural Science Foundation of China
Natural Science Foundation of Hubei Province of China
  1. Groenewegen A, Rutten FH, Mosterd A, et al., 2020, Epidemiology of heart failure. Eur J Heart Fail, 22: 1342–1356.


  1. Von Lueder TG, Krum H, 2015, New medical therapies for heart failure. Nat Rev Cardiol, 12: 730–740.


  1. Gjesdal O, Bluemke DA, Lima JA, 2011, Cardiac remodeling at the population level--risk factors, screening, and outcomes. Nat Rev Cardiol, 8: 673–685.


  1. Schiattarella GG, Hill JA, 2015, Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation, 131: 1435–1447.


  1. Floras JS, 2009, Sympathetic nervous system activation in human heart failure: Clinical implications of an updated model. J Am Coll Cardiol, 54: 375–385.


  1. Florea VG, Cohn JN, 2014, The autonomic nervous system and heart failure. Circ Res, 114: 815–1826.


  1. Floras JS, Ponikowski P, 2015, The sympathetic/ parasympathetic imbalance in heart failure with reduced ejection fraction. Eur Heart J, 36: 1974–1982b.


  1. Armour JA, 2004, Cardiac neuronal hierarchy in health and disease. Am J Physiol Regul Integr Comp Physiol, 287: R262–R271.


  1. Kember G, Armour JA, Zamir M, 2011, Neural control of heart rate: The role of neuronal networking. J Theor Biol, 277: 41–47.


  1. Armour JA, 2008, Potential clinical relevance of the “little brain” on the mammalian heart. Exp Physiol, 93: 165–176. https://10.1113/expphysiol.2007.041178


  1. Ardell JL, Armour JA, 2016, Neurocardiology: Structure-based function. Compr Physiol, 6: 1635–1653.


  1. Jaenig W, 2016, Neurocardiology: A neurobiologist’s perspective. J Physiol, 594: 3955–3962.


  1. Shivkumar K, Ajijola OA, Anand I, et al., 2016, Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics. J Physiol, 594: 3911–3954.


  1. Armour JA, 2011, Physiology of the intrinsic cardiac nervous system. Heart Rhythm, 8: 739.


  1. Sampaio KN, Mauad H, Spyer KM, et al., 2003, Differential chronotropic and dromotropic responses to focal stimulation of cardiac vagal ganglia in the rat. Exp Physiol, 88: 315–327.


  1. Galoyan A, Srapionian R, Arora RC, et al., 2001, Responsiveness of intrinsic cardiac neurons to left atrial and hypothalamic cardioactive peptides. Auton Neurosci, 92: 11–20.


  1. Thompson GW, Collier K, Ardell JL, et al., 2000, Functional interdependence of neurons in a single canine intrinsic cardiac ganglionated plexus. J Physiol, 528: 561–571.


  1. Gagliardi M, Randall WC, Bieger D, et al., 1988, Activity of in vivo canine cardiac plexus neurons. Am J Physiol, 255: H789–H800.


  1. Beaumont E, Salavatian S, Southerland EM, et al., 2013, Network interactions within the canine intrinsic cardiac nervous system: Implications for reflex control of regional cardiac function. J Physiol, 591: 4515–4533.


  1. Rajendran PS, Challis RC, Fowlkes CC, et al., 2019, Identification of peripheral neural circuits that regulate heart rate using optogenetic and viral vector strategies. Nat Commun, 10: 1944.


  1. Fleming JW, Wisler PL, Watanabe AM, 1992, Signal transduction by G proteins in cardiac tissues. Circulation, 85: 420–433.


  1. Ondicova K, Mravec B, 2010, Multilevel interactions between the sympathetic and parasympathetic nervous systems: A minireview. Endocr Regul, 44: 69–75.


  1. Vizi ES, Kobayashi O, Torocsik A, et al., 1989, Heterogeneity of presynaptic muscarinic receptors involved in modulation of transmitter release. Neuroscience, 31: 259–267.


  1. Frank A, Bonney M, Bonney S, et al., 2012, Myocardial ischemia reperfusion injury: From basic science to clinical bedside. Semin Cardiothorac Vasc Anesth, 16: 123–132.


  1. Thayer JF, Lane RD, 2007, The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol, 74: 224–242.


  1. Beaumont E, Wright GL, Southerland EM, et al., 2016, Vagus nerve stimulation mitigates intrinsic cardiac neuronal remodeling and cardiac hypertrophy induced by chronic pressure overload in guinea pig. Am J Physiol Heart Circ Physiol, 310: H1349–H1359.


  1. Kawada T, Yamazaki Y, Akiyama T, et al., 2006, Vagal stimulation suppresses ischemia-induced myocardial interstitial norepinephrine release. Life Sci, 78: 882–887.


  1. He X, Zhao M, Bi X, et al., 2015, Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases. Br J Pharmacol, 172: 5489–5500.


  1. Gurbani S, Chayasirisobhon S, Cahan L, et al., 2016, Neuromodulation therapy with vagus nerve stimulation for intractable epilepsy: A 2-year efficacy analysis study in patients under 12 years of age. Epilepsy Res Treat, 2016: 9709056.


  1. Binnie CD, 2000, Vagus nerve stimulation for epilepsy: A review. Seizure, 9: 161–169.


  1. Nahas Z, Marangell LB, Husain MM, et al., 2005, Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry, 66: 1097–1104.


  1. Bonaz B, Sinniger V, Hoffmann D, et al., 2016, Chronic vagus nerve stimulation in Crohn’s disease: A 6-month follow-up pilot study. Neurogastroenterol Motil, 28: 948–953.


  1. Koopman FA, Chavan SS, Miljko S, et al., 2016, Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci U S A, 113: 8284–8289.


  1. De Leeuw PW, Bisognano JD, Bakris GL, et al., 2017, Sustained reduction of blood pressure with baroreceptor activation therapy: Results of the 6-year open follow-up. Hypertension, 69: 836–843.


  1. Horbach T, Meyer G, Morales-Conde S, et al., 2016, Closed-loop gastric electrical stimulation versus laparoscopic adjustable gastric band for the treatment of obesity: A randomized 12-month multicenter study. Int J Obes (Lond), 40: 1891–1898.


  1. Salavatian S, Beaumont E, Longpré JP, et al., 2016, Vagal stimulation targets select populations of intrinsic cardiac neurons to control neurally induced atrial fibrillation. Am J Physiol Heart Circ Physiol, 311: H1311–H1320.


  1. Stavrakis S, Humphrey MB, Scherlag B, et al., 2017, Low-level vagus nerve stimulation suppresses post-operative atrial fibrillation and inflammation: A randomized study. JACC Clin Electrophysiol, 3: 929–938.


  1. Premchand RK, Sharma K, Mittal S, et al., 2016, Extended follow-up of patients with heart failure receiving autonomic regulation therapy in the ANTHEM-HF study. J Card Fail, 22: 639–642.


  1. Zannad F, De Ferrari GM, Tuinenburg AE, et al., 2015, Chronic vagal stimulation for the treatment of low ejection fraction heart failure: Results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J, 36: 425–433.


  1. Gold MR, Van Veldhuisen DJ, Hauptman PJ, et al., 2016, Vagus nerve stimulation for the treatment of heart failure: The INOVATE-HF trial. J Am Coll Cardiol, 68: 149–158.


  1. Beaumont E, Southerland EM, Hardwick JC, et al., 2015, Vagus nerve stimulation mitigates intrinsic cardiac neuronal and adverse myocyte remodeling postmyocardial infarction. Am J Physiol Heart Circ Physiol, 309: H1198–H1206.


  1. Salavatian S, Beaumont E, Gibbons D, et al., 2017, Thoracic spinal cord and cervical vagosympathetic neuromodulation obtund nodose sensory transduction of myocardial ischemia. Auton Neurosci, 208: 57–65.


  1. Premchand RK, Sharma K, Mittal S, et al., 2014, Autonomic regulation therapy via left or right cervical Vagus nerve stimulation in patients with chronic heart failure: Results of the ANTHEM-HF trial. J Card Fail, 20: 808–816.


  1. Libbus I, Nearing BD, Amurthur B, et al., 2016, Autonomic regulation therapy suppresses quantitative T-wave alternans and improves baroreflex sensitivity in patients with heart failure enrolled in the ANTHEM-HF study. Heart Rhythm, 13: 721–728.


  1. Mann DL, Deswal A, 2003, Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose. N Engl J Med, 349: 1963–1965.


  1. Castoro MA, Yoo PB, Hincapie JG, et al., 2011, Excitation properties of the right cervical vagus nerve in adult dogs. Exp Neurol, 227: 62–68.


  1. Byku M, Mann DL, 2016, Neuromodulation of the failing heart: Lost in translation? JACC Basic Transl Sci, 1: 95–106.


  1. Spuck S, Tronnier V, Orosz I, et al., 2010, Operative and technical complications of vagus nerve stimulator implantation. Neurosurgery, 67: 489–494.


  1. Wang Z, Yu L, Chen M, et al., 2014, Transcutaneous electrical stimulation of auricular branch of vagus nerve: A noninvasive therapeutic approach for post-ischemic heart failure. Int J Cardiol, 177: 676–677.


  1. Clancy JA, Mary DA, Witte KK, et al., 2014, Non-invasive vagus nerve stimulation in healthy humans reduces sympathetic nerve activity. Brain Stimul, 7: 871–877.


  1. Murray AR, Atkinson L, Mahadi MK, et al., 2016, The strange case of the ear and the heart: The auricular vagus nerve and its influence on cardiac control. Auton Neurosci, 199: 48–53.


  1. Chen M, Yu L, Liu Q, et al., 2015, Low level tragus nerve stimulation is a non-invasive approach for anti-atrial fibrillation via preventing the loss of connexins. Int J Cardiol, 179: 144–145.


  1. Stavrakis S, Humphrey MB, Scherlag BJ, et al., 2015, Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation. J Am Coll Cardiol, 65: 867–875.


  1. Wang Z, Yu L, Wang S, et al., 2014, Chronic intermittent low-level transcutaneous electrical stimulation of auricular branch of vagus nerve improves left ventricular remodeling in conscious dogs with healed myocardial infarction. Circ Heart Fail, 7: 1014–1021.


  1. Yu L, Huang B, Po SS, et al., 2017, Low-level tragus stimulation for the treatment of ischemia and reperfusion injury in patients with ST-Segment elevation myocardial infarction: A proof-of-concept study. JACC Cardiovasc Interv, 10: 1511–1520.


  1. Montgomery KL, Iyer SM, Christensen AJ, et al., 2016, Beyond the brain: Optogenetic control in the spinal cord and peripheral nervous system. Sci Transl Med, 8: 337rv5.


  1. Maimon BE, Sparks K, Srinivasan S, et al., 2018, Spectrally distinct channelrhodopsins for two-colour optogenetic peripheral nerve stimulation. Nat Biomed Eng, 2: 485–496.


  1. Towne C, Montgomery KL, Iyer SM, et al., 2013, Optogenetic control of targeted peripheral axons in freely moving animals. PLoS One, 8: e72691.


  1. Liske H, Towne C, Anikeeva P, et al., 2013, Optical inhibition of motor nerve and muscle activity in vivo. Muscle Nerve, 47: 916–921.


  1. Iyer SM, Vesuna S, Ramakrishnan C, et al., 2016, Optogenetic and chemogenetic strategies for sustained inhibition of pain. Sci Rep, 6: 30570.


  1. Hudry E, Vandenberghe LH, 2019, Therapeutic AAV gene transfer to the nervous system: A clinical reality. Neuron, 101: 839–862.


  1. Naso MF, Tomkowicz B, Perry WL 3rd, et al., 2017, Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs, 31: 317–334.


  1. Rodrigues GA, Shalaev E, Karami TK, et al., 2019, Pharmaceutical development of AAV-based gene therapy products for the eye. Pharm Res, 36: 29.


  1. Fontaine AK, Futia GL, Rajendran PS, et al., 2021, Optical vagus nerve modulation of heart and respiration via heart-injected retrograde AAV. Sci Rep, 11: 3664.


  1. Bates MC, Stone GW, Chen CY, et al., 2020, Device profile of the MobiusHD EVBA system for the treatment of resistant hypertension: Overview of its mechanism of action, safety and efficacy. Expert Rev Med Devices, 17: 649–658.


  1. Olsson L, Swedberg GS, Clark AL, et al., 2005, Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: A systematic review. Eur Heart J, 26: 778–793.


  1. Cleland JG, Daubert JC, Erdmann E, et al., 2005, The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med, 352: 1539–1549.


  1. Gronda E, Seravalle G, Trevano FQ, et al., 2015, Long-term chronic baroreflex activation: Persistent efficacy in patients with heart failure and reduced ejection fraction. J Hypertens, 33: 1704–1708.


  1. Dell’Oro R, Gronda E, Seravalle G, et al., 2017, Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: Final 43-month study report. J Hypertens, 35: 2532–2536.


  1. Ambrosioni E, Bacchelli S, Esposti DD, et al., 2001, Beta-blockade in hypertension and congestive heart failure. J Cardiovasc Pharmacol, 38 Suppl 3: S25–S31.


  1. Writing Committee Members, Yancy CW, Jessup M, et al., 2013, 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 128: e240–e327.


  1. Rienstra M, Damman K, Mulder BA, et al., 2013, Beta-blockers and outcome in heart failure and atrial fibrillation: A meta-analysis. JACC Heart Fail, 1: 21–28.


  1. McMurray JJ, Adamopoulos S, Anker SD, et al., 2012, ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail, 33: 803–869.


  1. Brophy JM, Joseph L, Rouleau JL, 2001, Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med, 134: 550–560.


  1. Chidsey CA, Harrison DC, Braunwald E, 1962, Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. N Engl J Med, 267: 650–654.


  1. Phan TT, Shivu GN, Abozguia K, et al., 2010, Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail, 3: 29–34.


  1. Ueda T, Kawakami R, Nishida T, et al., 2015, Left ventricular ejection fraction (EF) of 55% as cutoff for late transition from heart failure (HF) with preserved EF to HF with mildly reduced EF. Circ J, 79: 2209–2215.


  1. Borlaug BA, Melenovsky V, Russell SD, et al., 2006, Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation, 114: 2138–2147.


  1. Grassi G, Seravalle G, Esler M, 2020, Sympathomodulation in congestive heart failure: From drugs to devices. Int J Cardiol, 321: 118–125.


  1. Mahfoud F, Lüscher TF, Andersson B, et al., 2013, Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J, 34: 2149–2157.


  1. Esler MD, Krum H, Sobotka PA, et al., 2010, Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet, 376: 1903–1909.


  1. Bhatt DL, Kandzari DE, O’Neill WW, et al., 2014, A controlled trial of renal denervation for resistant hypertension. N Engl J Med, 370: 1393–1401.


  1. 2000, Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation, 101: 378–384.


  1. Sharp TE 3rd, Lefer DJ, 2021, Renal denervation to treat heart failure. Annu Rev Physiol, 83: 39–58.


  1. Polhemus DJ, Trivedi RK, Gao J, et al., 2017, Renal sympathetic denervation protects the failing heart via inhibition of neprilysin activity in the Kidney. J Am Coll Cardiol, 70: 2139–2153.


  1. Ogawa M, Zhou S, Tan AY, et al., 2007, Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure. J Am Coll Cardiol, 50: 335–343.


  1. Singh S, Sayers S, Walter JS, et al., 2013, Hypertrophy of neurons within cardiac ganglia in human, canine, and rat heart failure: The potential role of nerve growth factor. J Am Heart Assoc, 2: e000210.


  1. Pêgo-Fernandes PM, Moreira LF, Souza GE, et al., 2010, Endoscopic left sympathetic blockade in the treatment for dilated cardiomyopathy. Arq Bras Cardiol, 95: 685–690.


  1. Sun G, Liu F, Qu R, 2017, Effect of high thoracic sympathetic nerve block on serum collagen biomarkers in patients with chronic heart failure. Cardiology, 136: 102–107.


  1. Vaseghi M, Barwad P, Corrales FJ, et al., 2017, Cardiac sympathetic denervation for refractory ventricular arrhythmias. J Am Coll Cardiol, 69: 3070–3080.


  1. Llewellyn-Smith IJ, Martin CL, Arnolda LF, et al., 1999, Retrogradely transported CTB-saporin kills sympathetic preganglionic neurons. Neuroreport, 10: 307–312.


  1. Lujan HL, Palani G, Chen Y, et al, 2009, Targeted ablation of cardiac sympathetic neurons reduces resting, reflex and exercise-induced sympathetic activation in conscious rats. Am J Physiol Heart Circ Physiol, 296: H1305–H1311.


  1. Lujan HL, Palani G, Peduzzi JD, et al., 2010, Targeted ablation of mesenteric projecting sympathetic neurons reduces the hemodynamic response to pain in conscious, spinal cord-transected rats. Am J Physiol Regul Integr Comp Physiol, 298: R1358–R1365.


  1. Schwartz PJ, 2014, Cardiac sympathetic denervation to prevent life-threatening arrhythmias. Nat Rev Cardiol, 11: 346–353.


  1. Schwartz PJ, Stone HL, Brown AM, 1976, Effects of unilateral stellate ganglion blockade on the arrhythmias associated with coronary occlusion. Am Heart J, 92: 589–599.


  1. Beal MW, 2000, Acupuncture and Oriental body work: Traditional and biomedical concepts in holistic care: History and basic concepts. Holist Nurs Pract, 14: 69–78.


  1. 1998, NIH consensus conference. Acupuncture. JAMA, 280: 1518–1524.


  1. Li J, Li J, Chen Z, et al., 2012, The influence of PC6 on cardiovascular disorders: A review of central neural mechanisms. Acupunct Med, 30: 47–50.


  1. Li P, Longhurst JC, 2010, Neural mechanism of electroacupuncture’s hypotensive effects. Auton Neurosci, 157: 24–30.


  1. Zhou W, Longhurst JC, 2012, Neuroendocrine mechanisms of acupuncture in the treatment of hypertension. Evid Based Complement Alternat Med, 2012: 878673.


  1. Chao DM, Shen LL, Tjen AL, et al., 1999, Naloxone reverses inhibitory effect of electroacupuncture on sympathetic cardiovascular reflex responses. Am J Physiol, 276: H2127–H2134.


  1. Li P, Pitsillides KF, Rendig SV, et al., 1998, Reversal of reflex-induced myocardial ischemia by median nerve stimulation: A feline model of electroacupuncture. Circulation, 97: 1186–1194.


  1. Li P, Tjen-A-Looi SC, Longhurst JC, 2006, Excitatory projections from arcuate nucleus to ventrolateral periaqueductal gray in electroacupuncture inhibition of cardiovascular reflexes. Am J Physiol Heart Circ Physiol, 290: H2535–H2542.


  1. Zhou W, Fu LW, Tjen-A-Looi SC, et al., 2005, Afferent mechanisms underlying stimulation modality-related modulation of acupuncture-related cardiovascular responses. J Appl Physiol (1985), 98: 872–880.


  1. Lujan HL, Kramer VJ, DiCarlo SE, 2007, Electroacupuncture decreases the susceptibility to ventricular tachycardia in conscious rats by reducing cardiac metabolic demand. Am J Physiol Heart Circ Physiol, 292: H2550–H2555.


  1. Richter A, Herlitz J, Hjalmarson A, 1991, Effect of acupuncture in patients with angina pectoris. Eur Heart J, 12: 175–178.


  1. Ohsawa H, Okada K, Nishijo K, et al., 1995, Neural mechanism of depressor responses of arterial pressure elicited by acupuncture-like stimulation to a hindlimb in anesthetized rats. J Auton Nerv Syst, 51: 27–35.


  1. Yamamoto H, Kawada T, Kamiya A, et al., 2008, Electroacupuncture changes the relationship between cardiac and renal sympathetic nerve activities in anesthetized cats. Auton Neurosci, 144: 43–49.


  1. Ma L, Cui B, Shao Y, et al., 2014, Electroacupuncture improves cardiac function and remodeling by inhibition of sympathoexcitation in chronic heart failure rats. Am J Physiol Heart Circ Physiol, 306: H1464–H1471.
Conflict of interest
The authors declare that they have no competing interests.
Back to top
Brain & Heart, Electronic ISSN: 2972-4139 Published by AccScience Publishing